Nektar Therapeutics
NKTR
$56.23
-$0.39-0.69%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -44.90M | -36.08M | -35.52M | -41.59M | -50.88M |
| Total Depreciation and Amortization | 151.00K | 190.00K | 196.00K | 214.00K | 426.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 523.00K | -5.95M | -3.27M | -778.00K | 1.55M |
| Change in Net Operating Assets | -68.00K | -23.12M | -10.17M | -3.58M | -146.00K |
| Cash from Operations | -44.30M | -64.96M | -48.76M | -45.74M | -49.05M |
| Capital Expenditure | -18.00K | -715.00K | -114.00K | -37.00K | -2.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -350.77M | 1.09M | -94.76M | 49.65M | 43.69M |
| Cash from Investing | -350.79M | 372.00K | -94.87M | 49.62M | 43.69M |
| Total Debt Issued | 93.12M | 38.26M | 142.59M | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 4.06M | 410.00K | 238.00K | 211.00K | 7.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 432.38M | 0.00 | -1.15M | -- | -- |
| Cash from Financing | 529.55M | 38.67M | 141.68M | 211.00K | 7.00K |
| Foreign Exchange rate Adjustments | -- | 0.00 | 1.00K | 6.00K | -1.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 134.46M | -25.92M | -1.96M | 4.09M | -5.36M |